United Therapeutics, Liquidia Settle Patent Litigation With $330.4M Payment
The settlement includes a $330.4 million aggregate payment to United Therapeutics and actions to remove the PH-ILD indication from Yutrepia’s label.
Story updates
11:13:13 AM UTC
SquawkNews
WASHINGTON (dpa-AFX) - Liquidia Corp. (LQDA), a biopharmaceutical company, announced that it has entered into a global settlement agreement with United Therapeutics Corp. (UTHR) resolving all six pending litigation matters between the companies.The litigation primarily centred on patent disputes in…
United Therapeutics and Liquidia settled multiple patent and related litigations. 4 million to United Therapeutics and steps to remove the PH-ILD indication from Yutrepia’s label.